Advertisement

Myelodysplastische Syndrome

  • Detlef Haase
  • Frauke Alves
  • Winfried Gassmann
Part of the Molekulare Medizin book series (MOLMED)

Zusammenfassung

Myelodysplastische Syndrome (MDS) sind eine heterogene Gruppe klonaler Erkrankungen hämatopoetischer Stammzellen mit der Kapazität zur myeloischen — und in seltenen Fällen — lymphatischen Differenzierung (Fialkow 1984; Janssen et al. 1989; Tefferi et al. 1990). Der Stammzelldefekt führt zu einer ineffektiven, dysplastischen Hämatopoese, die sich im peripheren Blut in Form von Anämie und/oder Leukozytopenie und/oder Thrombozytopenie äußert und zu funktionellen Störungen in allen 3 Zellreihen führen kann (Hamblin 1992). Im Gegensatz zu den peripheren Zytopenien findet sich im Knochenmark meist eine erhöhte Zelldichte. Häufig sind alle 3 Zellreihen gleichzeitig betroffen. Leitsymptom ist die therapierefraktäre (auf Gabe von Eisen, Vitamin B12 oder Folsäure nicht ansprechende) Anämie. Bei etwa 1/3 der Patienten kommt es zum Übergang in eine akute myeloische Leukämie (sekundäre AML).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aatola M, Armstrong E, Teerenhovi L, Borgström GH (1992) Clinical significance of the del(20q) chromosome in hematologic dsiorders. Cancer Genet Cytogenet 62:75–80PubMedCrossRefGoogle Scholar
  2. Abrahamson G, Boultwood J, Madden J et al. (1991) Clonality of cell populations in refractory anemia using combined approach of gene loss and X-linked restriction fragment length polymorphism-methylation analysis. Br J Haematol 79:550–555PubMedCrossRefGoogle Scholar
  3. Adamson DJ, Dawson AA, Benett B, King DJ, Haites NE (1995) p53 mutation in the myelodysplastic syndromes. Br J Haematol 89:61–66PubMedGoogle Scholar
  4. Anan K, Ito M, Misawa M et al. (1995) Clonal analysis of peripheral blood and hematopoietic colonies in patients with aplastic anaemia and refractory anaemia using the polymorphic short tandem repeat on the human androgen-recepor (humara) gene. Br J Haematol 89:838–844PubMedCrossRefGoogle Scholar
  5. Anastasi J, Feng J, Le Beau MM, Larson RA, Rowley JD, Vardiman JW (1993) Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion. Blood 81:1580–1585PubMedGoogle Scholar
  6. Aoki Y, Bainton DF, Finch CA et al. (1986) Annotation. Primary acquired sideroblastic anaemia. Br J Haematol 64:415–418CrossRefGoogle Scholar
  7. Appelbaum FR, Anderson JA (1998) Bone marrow transplantation for myelodysplasia in adults and children: when and who? Leuk Res 21:S35–S39CrossRefGoogle Scholar
  8. Asano H, Ohashi H, Ichihara M et al. (1994) Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes. Blood 84:588–594PubMedGoogle Scholar
  9. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W (1992) Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6/1:52–59PubMedGoogle Scholar
  10. Aul C, Gattermann N, Schneider W (1992) Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 82:358–367PubMedCrossRefGoogle Scholar
  11. Aul C, Gattermann N, Schneider W (1995) Epidemiological and etiological aspects of myelodysplastic syndromes. Leuk Lymphoma 16:247–262PubMedCrossRefGoogle Scholar
  12. Avivi I, Rosenbaum H, Levy Y, Rowe J (1999) Myelodysplastic syndrome and associated skin lesions: a review of the literature. Leuk Res 23/4:323–330PubMedCrossRefGoogle Scholar
  13. Bain BJ (1999) The relationship between the myelodysplastic syndromes and the myeloproliferative disorders. Leuk Lymphoma 34/5–6:443–449PubMedGoogle Scholar
  14. Bar-Eli M, Ahuja H, Gonzalez-Cadavid N, Foti A, Cline MJ (1989) Analysis of N-RAS exon-1 mutations in myelodysplastic syndromes by polymerase chain reaction and direct sequencing. Blood 73:281–283PubMedGoogle Scholar
  15. Bartram CR (1996) Molecular genetic aspects of myelodysplastic syndromes. Semin Hematol 33:139PubMedGoogle Scholar
  16. Baumann I, Herrmann M, Harms H, Püllhorn H, Kirchner T (1999) Apoptosis and T-Cells in MDS. Leuk Res [Suppl 1] 23:S20Google Scholar
  17. Benitez J, Carbonell F, Fayos JS, Heimpel H (1985) Karyotypic evolution in patients with myelodysplastic syndromes. Cancer Genet Cytogenet 16:157–167PubMedCrossRefGoogle Scholar
  18. Benitez J, Martinez FC, Toledo C, Fayos JS, Ramos C (1987) Leukemic transformation in patients with the 5q-alteration: analysis of the behaviour of the 5q-clones in preleukemic to leukemic phases. Cancer Genet Cytogenet 26:199–207PubMedCrossRefGoogle Scholar
  19. Bennett JM, Catovsky D, Daniel MT et al. (1976) Proposals for the classification of the acute leukemias. Br J Haematol 33:451PubMedCrossRefGoogle Scholar
  20. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199PubMedGoogle Scholar
  21. Bennett JM, Catovsky D, Daniel MT et al. (1985) Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103/4:620–625PubMedGoogle Scholar
  22. Bennett JM, Catovsky D, Daniel MT et al. (1994) The chronic leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Br J Haematol 87:746–754PubMedCrossRefGoogle Scholar
  23. Ben-Yehuda D, Krichevsky S, Caspi O et al. (1996) Microsatellite instability and p53 mutations in therapy-resatated leukemia suggest mutator phenotype. Blood 88:4296–4303PubMedGoogle Scholar
  24. Beran M, Estey E, O’Brien SM et al. (1998) Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia. Leuk Lymphoma 5–6, 521–531Google Scholar
  25. Beran M, Estey E, O’Brien S et al. (1999) Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukaemia. J Clin Oncol 17:2819–2830PubMedGoogle Scholar
  26. Blatt J, Jafe R, Deutsch M, Adkins JC (1986) Neurofibromatosis and childhood tumors. Cancer 57:1225–1229PubMedCrossRefGoogle Scholar
  27. Block M, Jacobson LO, Bethard WF (1953) Preleukemic acute human leukemia. JAMA 152:1018–1028Google Scholar
  28. Bloomfield CD, Lawrence D, Byrd JC et al. (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173–4179PubMedGoogle Scholar
  29. Bollag G, Clapp DW, Shih S et al. (1996) Loss of NF1 results in activation of the RAS pathway and leads to aberrant growth in hematopoietic cells. Nat Genet 12:144–148PubMedCrossRefGoogle Scholar
  30. Boultwood J, Fidler C (1995) Chromosomal deletions in myelodysplasia. Leuk Lymphoma 17:71–78PubMedCrossRefGoogle Scholar
  31. Boultwood J, Wainscoat JS (1994) The 5q-syndrome. Blood 84:3253PubMedGoogle Scholar
  32. Boultwood J, Rack K, Kelly S et al. (1991) Loss of both CSF1R (FMS) alleles in patients with myelodysplasia and a chromosome 5 deletion. Proc Natl Acad Sci USA 88:6167–6180CrossRefGoogle Scholar
  33. Boultwood J, Fidler C, Lewis S et al. (1993) Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q-chromosome in some patients with the 5q-syndrome. Blood 82:2611–2616PubMedGoogle Scholar
  34. Boultwood J, Fidler C, Strickson AJ et al. (2000) Transcription mapping of the 5q-syndrome cortical region: cloning of two novel genes and sequencing, expression, and mapping of a further six novel cDNAs. Genomics 66:26–34PubMedCrossRefGoogle Scholar
  35. Bowen D, Culligan D, Jacobs A (1991) The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. Br J Haematol 77:419PubMedCrossRefGoogle Scholar
  36. Brenner MK, Rill DR, Moen RC (1993) Gene-marking trace origin of relapse after autologous bone-marrow transplantation. Lancet 341:85–86PubMedCrossRefGoogle Scholar
  37. Campbell LJ, Garson OM (1994) The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders. Leukemia 8:67–71PubMedGoogle Scholar
  38. Chen H, Sandler DP, Taylor JA et al. (1996) Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 347:295–297PubMedCrossRefGoogle Scholar
  39. Cheng KC, Loeb LA (1993) Genomic instability and tumor progression: mechanistic considerations. Adv Cancer Res 60:121–156PubMedCrossRefGoogle Scholar
  40. Cheson BD (1998) Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. Leuk Res 22:S17–S21PubMedCrossRefGoogle Scholar
  41. Chitambar CR, Libnoch JA, Matthaeus WG, Ash RC, Ritch PS, Anderson T (1991) Evaluation of continuous-infusion low-dose 5-aza-cytidine in the treatment of myelodysplastic syndromes. Am J Hematol 37:100–104PubMedCrossRefGoogle Scholar
  42. Coiffier B, Adeleine P, Viala JJ et al. (1983) Dysmyelopoietic syndromes: a search for prognostic factors in 193 patients. Cancer 52:83PubMedCrossRefGoogle Scholar
  43. Crisan D (2000) Molecular mechanisms in myelodysplastic syndromes and implications for evolution to acute leukemias. Clin Lab Med 1:49–70Google Scholar
  44. Culligan DJ, Cachia P, Whittaker J, Jacobs A, Padua RA (1992) Clonal lymphocytes are detectable in only some cases of MDS. Br J Haematol 81:346–352PubMedCrossRefGoogle Scholar
  45. Davis RE, Greenberg PL (1998) Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. Leuk Res 22:767–777PubMedCrossRefGoogle Scholar
  46. DeCastro CM, Glockermann JP, Moore JO, Hartung C, Misuraca J (1999) Treatment of myelodysplastic syndromes (MDS) with amifostine. Blood [Suppl 1] 92:251bGoogle Scholar
  47. De Planque MM, Kluin-Neleman HC, Van Krieken HJM et al. (1988) Evolution of acquired severe aplastic anaemia to myelodysplasia and subsequent leukaemia in adults. Br J Haematol 70:55–62PubMedCrossRefGoogle Scholar
  48. De Witte T, Suciu S, Peetermans M et al. (1995) Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration: a pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 9:1805–1811PubMedGoogle Scholar
  49. De Witte T, Van Biezen A, Hermans J et al. (1997) Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood 90:3853–3857PubMedGoogle Scholar
  50. Dhodapkar MV, Li CY, Lust JA, Tefferi A, Phyliky RL (1994) Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood 84:1620–1627PubMedGoogle Scholar
  51. Dick JE, Lapidot T, Pflumio F (1991) Transplantation of normal and leukemic human bone marrow into immune-deficient mice: development of animal models for human hematopoiesis. Immunol Rev 124.25–43PubMedCrossRefGoogle Scholar
  52. Döhner K, Brown J, Hehmann U et al. (1998) Molecular cytogenetic characterization of a critical region in bands 7q35–7q36 deleted in malignant myeloid disorders. Blood 92:4031–4035PubMedGoogle Scholar
  53. Dreyfus F, Bouscary D, Melle J, Ribrag V, Guesnu M, Varet B (1995) Expression of Evi-1 gene in myelodysplastic syndrome. Leukemia 9:203–205PubMedGoogle Scholar
  54. Farrow A, Jacobs A, West RR (1989) Myelodysplasia, chemical exposure, and other environmental factors. Leukemia 3:33–35PubMedGoogle Scholar
  55. Feldman P, Bryon P, Gentilhomme O, et al. (1988) The syndrome of abnormal chromatin clumping in leucocytes: a myelodysplastic disorder with proliferative features? Br J Haematol 70:49CrossRefGoogle Scholar
  56. Fenaux P, Morel P, Lai JL (1996) Cytogenetics of myelodysplastic syndromes. Semin Hematol 33:127PubMedGoogle Scholar
  57. Fialkow PJ (1984) Clonal evolution of human myeloid leukemias. In: Bishop JM, Rowley JD, Greaves M (eds) Genes and cancer. Liss, New York, pp 215–226Google Scholar
  58. Finiewicz KJ, Olopade OI (1999) Pathogenesis of early leukemia and lymphoma. In: Srivastava S, Henson DE, Gazdar A (eds) Molecular pathology of early cancer. IOS Press, Amsterdam, pp 233Google Scholar
  59. Fischer K, Frohling S, Scherer SW et al. (1997) Molecular cytogenetic delineation of deletions and translocations involving band 7q22 in myeloid leukemias. Blood 89:2036–2041PubMedGoogle Scholar
  60. Fishel R, Lescoe MK, Rao MRS et al. (1993) The human mutator gene homologue MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 61:1027–1038CrossRefGoogle Scholar
  61. Fohlmeister I, Fischer R, Modder B et al. (1985) Aplastic anaemia and the hypocellular myelodysplastic syndrome: histomorphological, diagnostic, and prognostic features. J Clin Pathol 38:1218PubMedCrossRefGoogle Scholar
  62. Fonatsch C (1999) Genetik der Leukämien. Med Genet 10:303–306Google Scholar
  63. Fourcar K, Langdon RM II, Armitage JO et al. (1985) Myelodysplastic syndromes: a clinical and pathologic analysis of 109 cases. Cancer 56:553CrossRefGoogle Scholar
  64. Gahn B, Haase D, Unterhalt M et al. (1996) De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. Leukemia 10:946–951PubMedGoogle Scholar
  65. Ganser A, Hoelzer D (1996) Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Semin Hematol 33:186–195PubMedGoogle Scholar
  66. Ganser A, Seipelt G, Lindemann A et al. (1990) Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 76:455–462PubMedGoogle Scholar
  67. Garcia S, Sanz MA, Amigo V et al. (1988) Prognostic factors in chronic myelodysplastic syndromes: a multivariate analysis in 107 cases. Am J Hematol 27:163PubMedCrossRefGoogle Scholar
  68. Gattermann N (1999) From sideroblastic anemia to the role of mitochondrial DNA mutations in MDS. Allan Jacobs Memorial Lecture, 5th International Symposium on Myelodysplastic Syndromes, Prague, April 21–24, 1999Google Scholar
  69. Gattermann N, Aul C, Schneider W (1990) Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol 74:45–52PubMedCrossRefGoogle Scholar
  70. Geddes AD, Bowen DT, Jacobs A (1990) Clonal karyotype abnormalities and clinical progress in the myelodysplastic syndrome. Br J Haematol 76:194–202PubMedCrossRefGoogle Scholar
  71. Geraedts JPM, Weber RFA, Kerkhofs H, Leeksma CHW (1980) The preleukemic syndrome. Acta Med Scand 207:447–454PubMedCrossRefGoogle Scholar
  72. Gerritsen WR, Donohue J, Bauman J et al. (1992) Clonal analysis of myelodysplastic syndrome: monosomy 7 is expressed in the myeloid lineage, but not in the lymphoid lineage as detected by fluorescent in situ hybridization. Blood 80:217–224PubMedGoogle Scholar
  73. Germing U, Gattermann N, Minning H, Heyll A, Aul C (1998) Problems in the classification of CMML — dysplastic versus proliferative type. Leuk Res 22:871–878PubMedCrossRefGoogle Scholar
  74. Germing U, Gattermann N, Aivado M, Hildebrandt B, Aul C (2000) Two types of acquired idiopathic sideroblastic anaemia (AISH): a time-tested distinction. Br J Haematol 108:724–728PubMedCrossRefGoogle Scholar
  75. Gibson S, Leung B, Squire JA et al. (1993) Identification, cloning and characterization of a novel human T-cell-specific tyrosine kinase located at the hematopoietin complex on chromosome 5q. Blood 82:1561–1572PubMedGoogle Scholar
  76. Golub TR, Barker GF, Lovett M, Gilliland DG (1994) Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307–316PubMedCrossRefGoogle Scholar
  77. Greenberg PL (1983) The smouldering leukemic states: clinical and biologic features. Blood 61:1035–1044PubMedGoogle Scholar
  78. Greenberg P, Taylor K, Larson R et al. (1983) Phase III randomised multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS). Blood [Suppl 1] 82:196Google Scholar
  79. Greenberg P, Cox C, LeBeau MM et al. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088PubMedGoogle Scholar
  80. Grimwade D, Walker H, Oliver F et al. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92:2322–2333PubMedGoogle Scholar
  81. Grossi A, Fabbri A, Santini V et al. (1998) Amifostine as a single agent or in combination regimen with low-dose ARA-C in the treatment of myelodysplastic syndromes. Blood [Suppl 1] 92:632aGoogle Scholar
  82. Gupta R, Abdalla SH, Bain BJ (1999) Thrombocytosis with sideroblastic erythropoiesis: a mixed myeloproliferative myelodysplastic syndrome. Leuk Lymphoma 34:615–619PubMedGoogle Scholar
  83. Gyger M, Bonny Y, Forest L (1982) Childhood monosomy 7 syndrome. Am J Hematol 13:329–334PubMedCrossRefGoogle Scholar
  84. Gyger M, Perreault C, Pichette R, Forest L, Lussier P (1986) Interstitial deletion of the long arm of chromosom 5 (5q-) in leukemia and other hematological disorders: clinical and biological relevance of variable breakpoint patterns. Leuk Res 10:9–15PubMedCrossRefGoogle Scholar
  85. Haase D, Fonatsch C, Freund M (1992) Karyotype instability in myelodysplastic syndromes — a specific step in pathogenesis preceding clonal chromosome anomalies. Leuk Lymphoma 8:221–228PubMedCrossRefGoogle Scholar
  86. Haase D, Fonatsch C, Freund M et al. (1995 a) Cytogenetic findings in 179 patients with myelodysplastic syndromes (MDS). Ann Hematol 70:171–187PubMedCrossRefGoogle Scholar
  87. Haase D, Feuring-Buske M, Könemann S et al. (1995 b) Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood 86:2906–2912PubMedGoogle Scholar
  88. Haase D, Freund M, Heußner P, Fonatsch C (1996) Cytogenetic follow-up of 13 patients with myelodysplastic syndromes (MDS) treated with granulocyte-macrophage colony-stimulating factor (GM-CSF). Tumordiagn Ther 17:74–81Google Scholar
  89. Haase D, Feuring-Buske M, Schäfer C et al. (1997 a) Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117. Leukemia 11:674–679PubMedCrossRefGoogle Scholar
  90. Haase D, Schanz J, Fonatsch C et al. (1997b) Correlation of karyotype with clinical features and prognosis in 349 patients with MDS. Leuk Res [Suppl 1] 21: 50Google Scholar
  91. Haase D, Schulz TG, Wörmann B et al. (1998) Association of GSTM1-deficiency with complex karyotype abnormalities in patients with de novo AML, MDS and with therapy-induced AML. Blood [Suppl 1] 92:1280Google Scholar
  92. Haase D, Schulz T, Wörmann B et al. (1999) Deletions of GST isoenzymes Ml and Tl as risk factors for therapy-induced AML and MDS and MDS and AML with complex karyotype abnormalities. Leuk Res [Suppl 1] 23:94Google Scholar
  93. Harada S, Komatsu H, Seto M et al. (1998) Microsatellite instability is rare in the clinical course of myelodysplastic syndrome studied with DNA from fresh and paraffin-embedded tissues. J Cancer Res Clin Oncol 124:231–235PubMedCrossRefGoogle Scholar
  94. Hamblin T (1992) Clinical features of MDS. Leuk Res 16:89–93PubMedCrossRefGoogle Scholar
  95. Hamilton-Patterson JL (1949) Preleukaemic anemia. Acta Hematol 2:309–316CrossRefGoogle Scholar
  96. Harris NL, Jaffe ES, Diebold J, et al. (1999) World health organization. Classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting — Airlie House, Virginia, November 1997. J Clin Oncol 17:3835–3849PubMedGoogle Scholar
  97. Heaney ML, Golde DW (1999) Myelodysplasia. N Engl J Med 340:1649–1660PubMedCrossRefGoogle Scholar
  98. Heilmeyer L (1953) The sidero-achrestic anemias. German Med Monthly 4:403–406Google Scholar
  99. Heim S, Mitelman F (1986) Chromosome abnormalities in the myelodysplastic syndromes. Clin Haematol 15:1003–1021PubMedGoogle Scholar
  100. Hellström-Lindberg E, Birgegard G, Carlsson M et al. (1993) A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma 11:221–228PubMedCrossRefGoogle Scholar
  101. Hellström-Lindberg E, Ahlgren T, Beguin Y (1998) treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow- up of 71 patients. Blood 92:68–75PubMedGoogle Scholar
  102. Helmstadter V, Arnold H, Blume KG, Uhl N, Hunstein W (1977) Acquired pyruvate kinase deficiency with hemolysis in preleukemia. Acta Haematol 57:339–343PubMedCrossRefGoogle Scholar
  103. Hofmann W-K, Seipelt G, Kalina U, Hoelzer D (2000) New aspects of the treatment of patients with low-risk myelodysplastic syndromes. Onkologie 23:12–16CrossRefGoogle Scholar
  104. Horiike S, Taniwaki M, Misawa S, Abe T (1988) Chromosome abnormalities and karyotype evolution in 83 patients with myelodysplastic syndrome and predictive value for prognosis. Cancer 62:1129–1138PubMedCrossRefGoogle Scholar
  105. Horiike S, Misawa S, Nakai H et al. (1994) N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia 8:1331–1336PubMedGoogle Scholar
  106. Horwitz M (1997) The genetics of familial leukemia. Leukemia 11:1347–1359PubMedCrossRefGoogle Scholar
  107. Hsu TC (1983) Genetic instability in the human population: a working hypothesis. Hereditas 98:1–9PubMedCrossRefGoogle Scholar
  108. Inokuchi K, Ikejima M, Watanabe A et al. (1995) Loss of expression of the human MSH3 gene in hematological malignancies. Biochem Biophys Res Commun 214:171–179PubMedCrossRefGoogle Scholar
  109. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558–561PubMedCrossRefGoogle Scholar
  110. Jacobs A (1991) Genetic abnormalities in myelodysplastic syndromes. Cancer Genet Cytogenet 56:1–6PubMedCrossRefGoogle Scholar
  111. Jacobs A, Clark RE (1986) Pathogenesis and clinical variations in the myelodysplastic syndromes. Clin Hematol 15:925–951Google Scholar
  112. Jacobs RH, Cornbleet MA, Vardiman JW, Larson RA, Le Beau MM, Rowley JD (1986) Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 67:1765–1772PubMedGoogle Scholar
  113. Janssen JWG, Buschle M, Lay ton M et al. (1991) Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood 73:248–254Google Scholar
  114. Jonasova A, Neuwirtova R, Mocikova K, Vozobulova V and the Czech MDS Cooperative Group (1999) Further experience with cyclosporin A in myelodysplastic syndromes. Leuk Res [Suppl 1] 23:213Google Scholar
  115. Kaneko H, Horiike S, Inazawa J, Nakai H, Misawa S (1995 a) Microsatellite instability is an early genetic event in myelodysplastic syndrome. Blood 86:1236–1237PubMedGoogle Scholar
  116. Kaneko H, Horiike S, Nakai H et al. (1995 b) Neurofibromatosis 1 gene (NF1) mutation is a rare genetic event in myelodysplastic syndrome regardless of the disease progression. Int J Hematol 61:113–116PubMedCrossRefGoogle Scholar
  117. Kaneko H, Misawa S, Horiike S, Nakai H, Kashima K (1995 c) TP53 mutations emerge at early phase of myelodyplastic syndrome and are associated with complex chromosomal abnormalities. Blood 85:2189–2193PubMedGoogle Scholar
  118. Kemp G, Rose P, Lurain J et al. (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomised control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101–2112PubMedGoogle Scholar
  119. Kere J, Ruutu T, De La Chapelle A (1987) Monosomy 7 in granulocytes and monocytes in myelodysplastic syndrome. N Engl J Med 316:499–503PubMedCrossRefGoogle Scholar
  120. Kerkhofs H, Hermans I, Haak HL, Leeksma CHW (1987) Utility of the FAB-classification for myelodysplastic syndromes. Investigation of prognostic factors in 237 cases. Br J Haematol 65:73–81PubMedCrossRefGoogle Scholar
  121. Killick SB, Marsh JC, Cavenagh JD et al. (1999) Antithymocyte globulin for the treatment of patients with “low risk”myelodysplastic syndromes. Blood [Suppl 1] 94:1371Google Scholar
  122. Kitagawa M, Saito I, Kuwata T et al. (1997) Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 11:2049–2054PubMedCrossRefGoogle Scholar
  123. Knapp RH, Dewald GW, Pierre RV (1985) Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin Proc 60:507–516PubMedGoogle Scholar
  124. Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823PubMedCrossRefGoogle Scholar
  125. Knuutila S, Teerenhovi L, Borgström GH (1984) Chromosome instability is associated with hypodiploid clones in myelodysplastic syndromes. Hereditas 101:19–30PubMedCrossRefGoogle Scholar
  126. Koeffler HP (1986) Human acute myeloid leukemia lines: models of leukemogenesis. Semin Hematol 23:223PubMedGoogle Scholar
  127. Koeffler HP (1996) Introduction: myelodysplastic syndromes. Semin Hematol 33:87PubMedGoogle Scholar
  128. Krause DS, Fackler MJ, Civin CI, May WS (1996) CD34: structure, biology, and clinical utility. Blood 87:1–13PubMedGoogle Scholar
  129. Lai J-L, Preudhomme C, Zandecki M et al. (1995) Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia 9:370–381PubMedGoogle Scholar
  130. Lapidot T, Sirard C, Vormoor J et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645–648PubMedCrossRefGoogle Scholar
  131. Lawrence J, Broudy VC, Magenis RE et al. (1987) Cytogenetic evidence for involvement of B-lymhocytes in acquired idiopathic sideroblastic anemias. Blood 70:1003–1005PubMedGoogle Scholar
  132. Le Beau MM (1992) Deletions of chromosome 5 in malignant myeloid disorders. Cancer Surv 15:143–159PubMedGoogle Scholar
  133. Le Beau MM, Pettenati MJ, Lemons RS et al. (1986) Assignment of the GM-CSF, CSF-1, and FMS genes to human chromosome 5 provides evidence for linkage of a family of genes regulating hematopoiesis and for their involvement in the deletion (5q) in myeloid disorders. Cold Spring Harbor Symp Q Biol 51:899–909Google Scholar
  134. Le Beau MM, Epstein ND, O’Brien et al. (1987) The interleukin 3 gene is located on human chromosome 5 and is deleted in myeloid leukemias with a deletion of 5q. Proc Nati Acad Sci 84:5913–5917CrossRefGoogle Scholar
  135. Le Beau MM, Lemons RS, Espinosa III R, Larson RA, Arai N, Rowöey JD (1989) Interleukin-4 and interleukin-5 map to human chromosome 5 in a region encoding growth factors and receptors and are deleted in myeloid leukemias with a del(5q). Blood 73:647–650PubMedGoogle Scholar
  136. Le Beau MM, Epinosa RI, Neumann WL et al. (1993) Cytogenetic and molecular delineation of the smallest commonly detected region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci USA 90:5484–5488PubMedCrossRefGoogle Scholar
  137. Le Beau MM, Espinosa IIIR, Davis EM, Eisenbart JD, Larson RA, Green ED (1996) Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 88:1930–1935PubMedGoogle Scholar
  138. Lee JJ, Kim H J, Chung IJ et al. (1999) Comparisons of prognostic scoring systems for myelodysplastic syndromes: a Korean multicenter study. Leuk Res 23:425–432PubMedCrossRefGoogle Scholar
  139. Leith CP, Kopecky KJ, Godwin J et al. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood 89:3323–3329PubMedGoogle Scholar
  140. Lepelley P, Soenen V, Preudhomme C, Merlat A, Cosson A, Fenaux P (1995) Bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis. Leukemia 9:726–730PubMedGoogle Scholar
  141. Levine EG, Bloomfield CD (1992) Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 19:47–84PubMedGoogle Scholar
  142. Li Y, Bollag G, Clark R et al. (1992) Somatic mutations in neurofibromatosis 1 gene in human tumors. Cell 69:275–281PubMedCrossRefGoogle Scholar
  143. List AF (1996) Role of multidrug resistance and its pharmacologic modulation in acute myeloid leukemia. Leukemia 10:937–942PubMedGoogle Scholar
  144. List AF (1999) Anti-apoptotic therapy: over-riding the cell death program in MDS. Leuk Res [Suppl 1] 23:S77Google Scholar
  145. List AF, Jacobs A (1992) Biology and pathogenesis of the myelodysplastic syndromes. Semin Oncol 19:14–24PubMedGoogle Scholar
  146. List AF, Brasfield F, Heaton R et al. (1997) Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 90:3364–3369PubMedGoogle Scholar
  147. Loeb LA (1998) Cancer cells exibit a mutator phenotype. Adv Cancer Res 72:25–26PubMedCrossRefGoogle Scholar
  148. Look AT (1998) Genes altered by chromosomal translocations in leukemias and lymphomas. In: Vogelstein B, Kinzler KW (eds) The genetic basis of human cancer. McGraw-Hill, New York, pp 109Google Scholar
  149. Lopingco MC, Perkins AS (1996) Molecular analysis of Evil, a zinc finger oncogene involved in myeloid leukemia. Curr Top Micobiol Immunol 211:211–222Google Scholar
  150. Lui B, Parsons R, Papadopoulos N et al. (1996) Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med 2:169–174CrossRefGoogle Scholar
  151. Luna-Fineman S, Shannon KM, Lange BJ (1995) Childhood monosomy 7: epidemiology, biology and mechanistic implications. Blood 85:1985–1994PubMedGoogle Scholar
  152. Luna-Fineman S, Shannon KM, Atwater SK et al. (1999) Myelodysplastic and myeloproliferative syndromes (MPS) of childhood: a study of 167 patients. Blood 93:459–466PubMedGoogle Scholar
  153. Lynch HT, Smyrk TC, Watson P et al. (1993) Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer. An updated review. Gastroenterology 104:1535–1549PubMedGoogle Scholar
  154. Maeck L, Haase D, Schoch C, Hiddemann W, Alves F (2002 a) Genetic instability in myelodysplastic syndrome: detection of microsatellite instability and loss of heterozygosity in bone marrow sampes with karyotype alterations. Br J HaematolGoogle Scholar
  155. Maeck L, Kohaus P, Haase D, Hiddemann W, Alves F (2002 b) Differential cellular expression of the human MSH2 protein in normal and myelodysplastic haematopoiesis. Br J HaematolGoogle Scholar
  156. Mandel K, Dror Y, Poon A, Freedman MH (1999) Definitive classification for pediatric myelodysplasia (MDS). Proc Annu Meet Am Soc Clin Oncol 18:A2178Google Scholar
  157. Marsh JCW, Geary CG (1991) Annotation. Is aplastic anaemia a pre-leukaemic disorder? Br J Haematol 77:447–452PubMedCrossRefGoogle Scholar
  158. Matsuda A, Jinnai I, Yagasaki F (1998) Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia. Leukemia 12:482–485PubMedCrossRefGoogle Scholar
  159. Matsuda A, Jinnai I, Yagasaki F et al. (1999) New system for assessing the prognosis of refractory anemia patients. Leukemia 13:1727–1734PubMedCrossRefGoogle Scholar
  160. McClure RF, Dewald GW, Hoyer JD, Hanson CA (1999) Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course. Br J Haematol 106:445–454PubMedCrossRefGoogle Scholar
  161. Mecucci C, Rege-Cambrin G, Michaux J-L, Tricot G, Van Den Berghe H (1986) Multiple chromosomally distinct cell populations in myelodysplastic syndromes and their possible significance in the evolution of the disease. Br J Haematol 64:699–706PubMedCrossRefGoogle Scholar
  162. Mehrotra B, George TI, Kavanau K et al. (1995) Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia. Blood 86:1139–1147PubMedGoogle Scholar
  163. Merchav S, Wagemaker G, Souza LM, Tatarsky I (1991) Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors. Leukemia 5:340–346PubMedGoogle Scholar
  164. Mielot F, Buisine J, Duchayne E et al. (1998) Myelodysplastic syndromes in childhood: is the FAB classification relevant? Report of 81 children from a French multicentre study. French Group of Cellular Hematology. Leuk Lymphoma 28:531–540PubMedGoogle Scholar
  165. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ (1997) Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 99:699–705PubMedCrossRefGoogle Scholar
  166. Morel P, Hebbar M, Lai J-L et al. (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 7:1315–1323PubMedGoogle Scholar
  167. Mori N, Morosetti R, Hoflehner E, Lubbert M, Mizoguchi H, Koeffler HP (2000) Allelic loss in the progression of myelodysplasic syndrome. Cancer Res 60:3039–3042PubMedGoogle Scholar
  168. Morosetti R, Koeffler HP (1996) Differentiation therapy in myelodysplastic syndromes. Semin Hematol 33:236–245PubMedGoogle Scholar
  169. Mufti GJ (1992) A guide to risk assessment in the primary myelodysplastic syndrome. Hematol Oncol Clin North Am 6:587–606PubMedGoogle Scholar
  170. Mufti GJ (1992) Chromosomal deletions in the myelodysplastic syndromes. Leuk Res 16:35–41PubMedCrossRefGoogle Scholar
  171. Mufti GJ, Stevens JR, Oscier DG et al. (1985) Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59:425PubMedCrossRefGoogle Scholar
  172. Nagarajan L (1995) Molecular analysis of the 5q- chromosome. Leuk Lymphoma 17:361–366PubMedCrossRefGoogle Scholar
  173. Nagarajan L, Zavadil J, Claxton D et al. (1994) Consistent loss of the D5S89 locus mapping telomeric to the interleukin gene cluster and centromeric to EGR-1 in patients with 5q- chromosome. Blood 83:199–208PubMedGoogle Scholar
  174. Neubauer A, Greenberg P, Negrin R, Ginzton N, Liu E (1994) Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes. Leukemia 8:638–641PubMedGoogle Scholar
  175. Newsham IF, Hadjistilianou T, Cavenne WK (1998) Retinoblastoma. In: Vogelstein B, Kinzler KW (eds) The genetic basis of human cancer. McGraw-Hill, New York, pp 363Google Scholar
  176. Nisse C, Lorthois C, Dorp V, Eloy E, Haguenoer JM, Fenaux P (1995) Exposure to occupational and environmental factors in myelodysplastic syndromes. Preliminary results of a case-control study. Leukemia 9:693–699PubMedGoogle Scholar
  177. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194:23–28PubMedCrossRefGoogle Scholar
  178. Nowell PC (1992) Chromosome abnormalities in myelodysplastic syndromes. Semin Oncol 19:25–33PubMedGoogle Scholar
  179. Nowell PC, Beas E (1989) Prognostic significance of single chromosome abnormalities in preleukemic states. Cancer Genet Cytogenet 42:1–7PubMedCrossRefGoogle Scholar
  180. Nowell PC, Besa EC, Stelmach T, Finan JB (1986) Chromosome studies in preleukemic states. Cancer 58:2571–2575PubMedCrossRefGoogle Scholar
  181. Nye JA, Peterson JM, Günther CV, Jonsen MD, Graves BJ (1990) Interaction of murine ets-1 with GGA-binding sites establishes the ETS domain as a new DNA-binding motif. Genes Dev 6:975–990CrossRefGoogle Scholar
  182. Ohyashiki K, Ohyashiki J, Oshimura M et al. (1983) Cytogenetic and in vitro culture studies on chronic myelomonocytic leukemia. Cancer 54:2468–2474CrossRefGoogle Scholar
  183. Okada M, Okamoto T, Yamada S et al. (1999) Good response to cyclosporine therapy in patients with myelodysplastic syndrome having the HLA-DRB11501 allele. Blood [Suppl 1] 94:1370Google Scholar
  184. Pagliuca A, Lay ton DM, Manoharan A et al. (1989) Myelofibrosis in primary myelodysplastic syndromes: a clinicomorphological study of 10 cases. Br J Haematol 71:499PubMedCrossRefGoogle Scholar
  185. Parker J, Mufti GJ (1996) Ras and myelodysplasia: lessons from the last decade. Semin Hematol 33:206–224PubMedGoogle Scholar
  186. Parker JE, Fishlock KL, Pagliuca A, Mufti GJ (1998) The role of apoptosis, proliferation and amifostine in the myelodysplastic syndromes (MDS) and AML secondary to MDS. Blood [Suppl 1] 92:1729Google Scholar
  187. Parovitchnikova E, Savchenko V, Mikhailova E et al. (1998) Cyclosporin A may be effective in different forms of myelodysplastic syndromes. Blood [Suppl 1] 92:633Google Scholar
  188. Pedersen B (1998) 5q(-) survival: importance of gender and deleted 5q bands and survival analysis based on 324 published cases. Leuk Lymphoma 31:325–334PubMedGoogle Scholar
  189. Pedersen-Bjeergard J, Philip P, Larsen SO et al. (1993) Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 12:1975–1986Google Scholar
  190. Pfeilstöcker M, Reisner R, Nosslinger T et al. (1999) Crossvalidation of prognostic scores in myelodysplastic on 386 patients from a single institution confirms importance of cytogenetics. Br J Haematol 106:455–463PubMedCrossRefGoogle Scholar
  191. Pierre RV, Catovsky D, Mufti GJ et al. (1989) Clinical-cytogenetic correlations in myelodysplasia (preleukemia). Cancer Genet Cytogenet 40:149–161PubMedCrossRefGoogle Scholar
  192. Quesnel B, Preudhomme C, Vanrumbeke M, Vachee A, Jai JL, Fenaux P (1994) Absence of rearrangement of neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 8:878–880PubMedGoogle Scholar
  193. Quesnel B, Guillerm G, Vereecque R et al. (1998) Methylation of the p15ink4b gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91:2985–2990PubMedGoogle Scholar
  194. Radlund A, Thiede T, Hansen S, Carlsson M, Engquist L (1995) Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol 54:153–156PubMedCrossRefGoogle Scholar
  195. Rasi V, Lintula R (1986) Platelet function in the myelodysplastic syndrome. Scand J Haematol [Suppl 45] 736:1Google Scholar
  196. Raza A, Gezer S, Mundle S et al. (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86:268–276PubMedGoogle Scholar
  197. Raza A, Mundle S, Shetty V (1996) Novel insights into the biology of myelodysplastic syndromes. Excessive apoptosis and the role of cytokines. Int J Hematol 63:265–278PubMedCrossRefGoogle Scholar
  198. Reiffers J, Stoppa AM, Atta M (1993) Autologous stem cell transplantation vs chemotherapy in adult patients with acute myeloid leukemia in first remission: the BGMT group experience. Nouv Rev Fr Hematol 135:17–19Google Scholar
  199. Reinhardt D, Haase D, Schoch C et al. (1998) Hemoglobin F in myelodysplastic syndrome. Ann Hematol 76:135–138PubMedCrossRefGoogle Scholar
  200. Reizenstein P, Dabrowski L (1991) Increasing prevalence of the myelodysplastic syndrome. An international Delphi study. Anticancer Res 11:1069–1070PubMedGoogle Scholar
  201. Ridge SA, Workwood M, Oscier D, Jacobs A, Padua RA (1990) Fms mutations in myelodysplastic, leukemic and normal subjects. Proc Natl Acad Sci USA 87:1377–1382PubMedCrossRefGoogle Scholar
  202. Rosati S, Mick R, Xu F et al. (1996) Refractory cytopenia with multilineage dysplasia: further characterization of an “unclassificable”myelodysplastic syndrome. Leukemia 10:20–26PubMedGoogle Scholar
  203. Roulston D, Espinosa III R, Stoffel M, Bell GI, Le Beau MM (1993) Molcular genetics of myeloid leukemia: identification of the commonly deleted segment of chromosome 20. Blood 82:3424–3429PubMedGoogle Scholar
  204. Russell M, List A, Greenberg P et al. (1994) Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 84:1243–1248PubMedGoogle Scholar
  205. Ruutu P (1986) Granulocyte function in myelodysplastic syndromes. Scand J Haematol [Suppl 45] 36:66–70CrossRefGoogle Scholar
  206. Saitoh K, Miura I, Takahashi N, Miura AB (1998) Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes. Blood 92:2886–2892PubMedGoogle Scholar
  207. Sanz GF, Sanz MA (1992) Prognostic factors in myelodysplastic syndromes. Leuk Res 16:77–86PubMedCrossRefGoogle Scholar
  208. Sanz GF, Sanz MA, Vallespi T et al. (1989) Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariante analysis of prognostic factors in 370 patients. Blood 74:395PubMedGoogle Scholar
  209. Sanz GF, Sanz MA, Greenberg PL (1998) Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 83:358–368PubMedGoogle Scholar
  210. Sawyers CL, Denny CT (1994) Chronic myelomonocytic leukemia: Tel-a-kinase what its all about. Cell 77:171–173PubMedCrossRefGoogle Scholar
  211. Schlessinger J, Ullrich A (1992) Growth factor signaling by receptor tyrosine kinases. Neuron 9:383–391PubMedCrossRefGoogle Scholar
  212. Schmitt-Graeff A, Mattern D, Kohler H, Hezel J, Lubbert M (2000) Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis. Pathologe 21:1–15PubMedCrossRefGoogle Scholar
  213. Schmetzer HM, Poleck B, Duell T, Gerhartz HH, Mittermuller J (2000) Cytogenetic and Southern blot analysis to demonstrate clonality and to estimate prognosis in patients with myelodysplastic syndromes. Ann Hematol 79:20–29PubMedCrossRefGoogle Scholar
  214. Schnittger S, Kinkelin U, Schoch C et al. (2000) Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 14:796–804PubMedCrossRefGoogle Scholar
  215. Schoch C, Haase D, Fonatsch C et al. (1997) The significance of trisomy 8 in de novo acute myeloid leukemia: the accompanying chromosome aberrations determine the prognosis. Br J Haematol 99:605–611PubMedCrossRefGoogle Scholar
  216. Seeker-Walker LM (1990) Prognostic and biological importance of chromosome findings in acute lymphoblastic leukemia. Cancer Genet Cytogenet 49:1–13CrossRefGoogle Scholar
  217. Shetty V, Mundle S, Alvi S et al. (1996) Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 20:891–900PubMedCrossRefGoogle Scholar
  218. Shounan Y, MacKenzie K, Dolnikov A, Miller M, Symonds G (1997) Myeloproliferative disease and myelodysplastic syndrome induced by transplantation of bone marrow cells expressing mutant p53. Leukemia 11:1641–1649PubMedCrossRefGoogle Scholar
  219. Siebert R, Grote W, Schlegelberger B (1998) Familiäres Auftreten hämatologischer Neoplasien. Medgen 10:310–312Google Scholar
  220. Silverman LR (1998) A randomized comparison of 5-azacytidine and supportive care in patients with myelodysplastic syndrome (MDS). Proc ASCO 17:14a, Abstract 53Google Scholar
  221. Solé F, Prieto L, Badia L et al. (1992) Cytogenetic studies in 112 cases of untreated myelodysplastic syndromes. Cancer Genet Cytogenet 64:12–20PubMedCrossRefGoogle Scholar
  222. Sole F, Espinet B, Sanz GF et al. (2000) Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol 108:346–356PubMedCrossRefGoogle Scholar
  223. Suciu S, Kuse R, Weh HJ, Hossfeld DK (1990) Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome. Cancer Genet Cytogenet 44:15–26PubMedCrossRefGoogle Scholar
  224. Sugimoto K, Hirano N, Toyoshima H et al. (1993) Mutations in p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 81:3022–3026PubMedGoogle Scholar
  225. Swolin B, Rödjer S, Westin J (1990) Bone marrow in vitro growth and cytogenetic studies in patients with FAB-classified primary myelodysplastic syndromes. Am J Hematol 34:175–180PubMedCrossRefGoogle Scholar
  226. Tang JL, Tien HF, Lin MT, Chen PJ, Chen YC (1998) P53 mutation in advanced stage of primary myelodysplastic syndrome. Anticancer Res 18:3757–3761PubMedGoogle Scholar
  227. Taniguchi T (1995) Cytokine signaling through nonreceptor protein tyrosine kinases. Science 268:251–255PubMedCrossRefGoogle Scholar
  228. Tasaka T, Lee S, Spira S et al. (1996) Infrequent microsatellite instability during the evolution of myelodysplastic syndrome to acute myelotic leukemia. Leuk Res 20:113–117CrossRefGoogle Scholar
  229. Tassin F, Dewe W, Schaaf N et al. (2000) A four-parameter index of marrow dysplasia has predictive value for survival in myelodysplasic syndromes. Leuk Lymphoma 36/5–6:485–496PubMedCrossRefGoogle Scholar
  230. Tefferi A, Thibodeau SN, Solberg LA (1990) Clonal studies in a myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. Blood 75:1770–1773PubMedGoogle Scholar
  231. Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. Science 260:816–819PubMedCrossRefGoogle Scholar
  232. Thiede T, Engquist L, Billstrom R (1988) Application of megakaryocytic morphology in diagnosing 5q-syndrome. Eur J Haematol 41:434PubMedCrossRefGoogle Scholar
  233. Tosi S, Scherer SW, Giudici G, Czepulkowski B, Biondi A, Kearney L (1999) Delineation of multiple deleted regions in 7q myeloid disorders. Genes Chromosomes Cancer 25:384–392PubMedCrossRefGoogle Scholar
  234. Toyama K, Ohyashiki K, Yoshida Y et al. (1993) Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 7:499–508PubMedGoogle Scholar
  235. Tricot G (1986) Evolution of the myelodysplastic syndromes. Br J Haematol 63:609–614PubMedCrossRefGoogle Scholar
  236. Tricot G, DeWolfe-Peeters C, Hendrick B, Verwilghen RL (1984) Bone marrow histology in myelodysplastic syndromes. Br J Haematol 57:423PubMedCrossRefGoogle Scholar
  237. Tricot G, Vlietinck R, Boogaerts MA et al. (1985) Prognostic factors in the myelodysplstic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br J Haematol 60:19PubMedCrossRefGoogle Scholar
  238. Uchida T, Ohashi H, Aoki E et al. (2000) Clonality analysis by methylation-specific PCR for the human androgen-receptor gene (HUMARA-MSP). Leukemia 14:207–121PubMedCrossRefGoogle Scholar
  239. Vallespi T, Torrabadella M, Julia A et al. (1985) Myelodysplastic syndromes: a study of 101 cases according to the FAB classification. Br J Haematol 61:83PubMedCrossRefGoogle Scholar
  240. Van den Berghe H, Vermaelen K, Mecucci C, Barbieri D, Tricot G (1985) The 5q- anomaly. Cancer Genet Cytogenet 17:189–255PubMedCrossRefGoogle Scholar
  241. Verbeek W, Wörmann B, Koch P et al. (1999) Results of a randomised double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes. J Cancer Res Clin Oncol 125:369–374PubMedCrossRefGoogle Scholar
  242. Verhoef GEG, Pittaluga S, De Wolf-Peeters C, Boogaerts MA (1995) FAB classification of myelodysplastic syndromes: merits and controversies. Ann Hematol 71:3–11PubMedCrossRefGoogle Scholar
  243. Von Leube (1900) Rapid verlaufende schwere Anämie mit gleichzeitiger leukämischer Veränderung des Blutbildes. Berlin Klin Wochenschr, Sitzung vom 15. Juni 1900:S 851Google Scholar
  244. Wang PW, Iannantuoni K, Davis EM, Espinosa III R, Stoffel M, Le Beau MM (1998) Refinement of the commonly deleted segment in myeloid leukemias with a del(20q). Genes Chromosomes Cancer 21:75–81PubMedCrossRefGoogle Scholar
  245. Warrington JA, Baily SK, Armstrong E et al. (1992) A radiation hybrid map of 18 growth factor, growth factor receptor, hormone receptor, or neurotransmitter receptor genes on the distal region of the long arm of chromosome 5. Genomics 13:803–808PubMedCrossRefGoogle Scholar
  246. Wattel E, Preudhomme C, Hecquet B et al. (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148–3157PubMedGoogle Scholar
  247. Weil SC, Rose VL (1986) A variant myelodysplastic syndrome with multilineage pelgeroid chromatin. Am J Pathol 85:176Google Scholar
  248. Westbrook CA, Keinanen MJ (1992) Myeloid malignancies and chromosome 5 deletions. Baillieres Clin Haematol 5:931–942PubMedCrossRefGoogle Scholar
  249. White AD, Jacobs A (1992) Peripheral blood chromosome aberrations in MDS. Cancer Genet Cytogenet 59:167–172PubMedCrossRefGoogle Scholar
  250. White AD, Hoy TG, Jacobs A (1994) Extended cytogenetic follow-up and clinical progress in patients with myelodysplastic syndromes (MDS). Leuk Lymphoma 12:401–412PubMedCrossRefGoogle Scholar
  251. Wijermans P, Luebbert M, Verhoef G et al. (1999) DNA demethylating therapy in MDS-the experience with 5-aza-2{pi}ft-deoxycytidine (decitabine). Blood [Suppl 1] 94:306aGoogle Scholar
  252. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG (1994) Establishing the incidence of myelodysplastic syndrome. Br J Haematol 87:743–745PubMedCrossRefGoogle Scholar
  253. Willmann CL (1998) Molecular genetic features of MDS. Leukemia 12:S2–S6Google Scholar
  254. Willmann CL (1999) Acute leukemias: a paradigm for the integration of new technologies in diagnosis and classification. Mod Pathol 12:218Google Scholar
  255. Willman CC, Sever CE, Pallavicini MG et al. (1993) Deletion of IRF-1, mapping to chromosome 5q31.1 in human leukemia and preleukemic myelodysplasia. Science 259:968–971PubMedCrossRefGoogle Scholar
  256. Wörmann B (1993) Implications of detection of minimal residual disease. Curr Opin Oncol 5:3–10PubMedGoogle Scholar
  257. Xie D, Hofmann WK, Mori N, Miller CW, Hoelzer D, Koeffler HP (2000) Allelotype analysis of the myelodysplastic syndrome. Leukemia 14:805–810PubMedCrossRefGoogle Scholar
  258. Yan X-Q, Brady G, Iscove NN (1994) Overexpression of PDGF-b in murine hematopoietic cells induces a lethal myeloproliferative syndrome in vivo. Oncogene 9:163–173PubMedGoogle Scholar
  259. Yoshida Y (1993) Hypothesis. Apoptosis may be the mechanism responsible for the intramedullary cell death in myelodysplasia. Leukemia 7:144–146PubMedGoogle Scholar
  260. Young NS, Molldrem J J, Maciejewski JP, Dunn DE, Barrett A (1999) Immune system inhibition of hematopoiesis in bone marrow failure in aplastic anemia and myelodysplasia: diagnostic, pathpohysiologic and clinical implications. Leuk Res [Suppl 1] 23:29Google Scholar
  261. Yunis JJ (1976) High resolution of human chromosomes. Science 191:1268–1270PubMedCrossRefGoogle Scholar
  262. Yunis JJ, Lobell M, Arnesen MA et al. (1988) Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acuite myelogenous leukaemia. Br J Haematol 68:189–194PubMedCrossRefGoogle Scholar
  263. Zhu Y-M, Das-Gypta EP, Russel NH (1999) Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood 94:733PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Detlef Haase
  • Frauke Alves
  • Winfried Gassmann

There are no affiliations available

Personalised recommendations